We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Compounds Found That Inhibit SARS

By HospiMedica staff writers
Posted on 27 Oct 2004
A number of compounds that effectively inhibit the spread of severe acute respiratory syndrome (SARS) have been found by researchers at the University of Hong Kong (HKU), working with Chembridge Corp. More...
(San Diego, CA, USA).

Dr. Richard Kao, research assistant professor in the HKU department of microbiology, and his team used chemical genetics methods to screen a Chembridge library of more than 50,000 compounds in an attempt to identify small molecules that stop the spread of the coronavirus. After finding a number of compounds, the team is now working on identifying the mechanisms by which these compounds work in an effort to bring a SARS cure to the marketplace.

"The pioneering works of Drs. Schreiber [Harvard University, Boston, MA, USA] and Stockwell [Massachusetts Institute of Technology, Boston, USA] have laid down the foundation of chemical genetics. We just followed their footsteps and extended this new research paradigm to emerging infectious diseases, an increasingly alarming problem regionally and globally.”

"Richard [Kao] and his team are to be congratulated on the way they have approached and tackled this problem, and I hope that the early-stage success gained in the search for a potential treatment for SARS will be repeated on other targets in the future,” said Reg Richardson, Ph.D., European marketing manager, Chembridge.

SARs affected more than 8,000 people, killing over 800, mainly in Hong Kong and China during the period April-June 2003.


Related Links:
U. of Hong Kong
Chembridge

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Electric Bed
DIXION Intensive Care Bed
Absorbable Monofilament Mesh
Phasix Mesh
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.